busulfan has been researched along with Genetic Diseases in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics." | 2.70 | A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. ( Aschan, J; Eber, S; Gungor, T; Hassan, M; Hassan, Z; Hentschke, P; Ljungman, P; Nilsson, C; Ringdén, O; Seger, R; Winiarski, J, 2002) |
| " This regimen was associated with durable donor engraftment and relatively low rates of regimen related toxicity (RRT); future alemtuzumab pharmacokinetic studies may improve outcomes, by allowing targeted alemtuzumab clearance to reduce graft rejection and promote more rapid immune reconstitution." | 1.42 | Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ( Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q, 2015) |
| "Busulfan doses were decreased in 69% of patients compared to conventional doses." | 1.31 | Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. ( Aulagner, G; Bertrand, Y; Bleyzac, N; Dai, Q; Galambrun, C; Janoly, A; Jelliffe, RW; Magron, P; Maire, P; Martin, P; Souillet, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Azim, H | 1 |
| Mahadeo, KM | 1 |
| Zhao, Q | 1 |
| Khazal, S | 1 |
| Kohn, DB | 1 |
| Crooks, GM | 1 |
| Shah, AJ | 1 |
| Kapoor, N | 1 |
| Geyer, MB | 1 |
| Jacobson, JS | 1 |
| Freedman, J | 1 |
| George, D | 1 |
| Moore, V | 1 |
| van de Ven, C | 1 |
| Satwani, P | 1 |
| Bhatia, M | 1 |
| Garvin, JH | 1 |
| Bradley, MB | 1 |
| Harrison, L | 1 |
| Morris, E | 1 |
| Della-Latta, P | 1 |
| Schwartz, J | 1 |
| Baxter-Lowe, LA | 1 |
| Cairo, MS | 1 |
| Hassan, M | 2 |
| Nilsson, C | 1 |
| Hassan, Z | 1 |
| Gungor, T | 1 |
| Aschan, J | 1 |
| Winiarski, J | 1 |
| Hentschke, P | 1 |
| Ringdén, O | 2 |
| Eber, S | 1 |
| Seger, R | 1 |
| Ljungman, P | 2 |
| Tsuji, Y | 1 |
| Imai, K | 1 |
| Morinishi, Y | 1 |
| Kogawa, K | 1 |
| Morino, M | 1 |
| Nonoyama, S | 1 |
| Békássy, AN | 1 |
| Oberg, G | 1 |
| Giorgiani, G | 1 |
| Bozzola, M | 1 |
| Locatelli, F | 1 |
| Picco, P | 1 |
| Zecca, M | 1 |
| Cisternino, M | 1 |
| Dallorso, S | 1 |
| Bonetti, F | 1 |
| Dini, G | 1 |
| Borrone, C | 1 |
| Styler, MJ | 1 |
| Crilley, P | 1 |
| Biggs, J | 1 |
| Moul, J | 1 |
| Copelan, E | 1 |
| Topolsky, D | 1 |
| Avalos, B | 1 |
| Penza, S | 1 |
| Sabol, P | 1 |
| Downs, K | 1 |
| Szer, J | 1 |
| Brodsky, I | 1 |
| Marks, DI | 1 |
| Rosales, F | 1 |
| Peylan-Ramu, N | 1 |
| Cividalli, G | 1 |
| Varadi, G | 1 |
| Or, R | 1 |
| Naparstek, E | 1 |
| Slavin, S | 1 |
| Nagler, A | 1 |
| Bolinger, AM | 1 |
| Zangwill, AB | 1 |
| Slattery, JT | 1 |
| Glidden, D | 1 |
| DeSantes, K | 1 |
| Heyn, L | 1 |
| Risler, LJ | 1 |
| Bostrom, B | 1 |
| Cowan, MJ | 1 |
| Bleyzac, N | 1 |
| Souillet, G | 1 |
| Magron, P | 1 |
| Janoly, A | 1 |
| Martin, P | 1 |
| Bertrand, Y | 1 |
| Galambrun, C | 1 |
| Dai, Q | 1 |
| Maire, P | 1 |
| Jelliffe, RW | 1 |
| Aulagner, G | 1 |
| Vellodi, A | 1 |
| Jurges, E | 1 |
| el-Tumi, M | 1 |
| Abdul-Ahad, A | 1 |
| Hobbs, JR | 1 |
1 trial available for busulfan and Genetic Diseases
| Article | Year |
|---|---|
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Topics: Adult; Age Factors; Busulfan; Child; Cyclophosphamide; Drug Administration Schedule; Drug Carriers; | 2002 |
10 other studies available for busulfan and Genetic Diseases
| Article | Year |
|---|---|
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclo | 2015 |
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antily | 2011 |
Successful unrelated cord blood transplantation for a patient with CD40 ligand deficiency.
Topics: Agammaglobulinemia; Busulfan; CD40 Antigens; Cord Blood Stem Cell Transplantation; Cyclophosphamide; | 2007 |
Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.
Topics: Adolescent; Adult; Alopecia; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, | 1995 |
Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Height; Bone Marrow Transplantation; Busulfan; | 1995 |
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child, | 1996 |
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1999 |
An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Genetic Diseases | 2000 |
Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Topics: Adolescent; Alkylating Agents; Area Under Curve; Bayes Theorem; Bone Marrow Transplantation; Busulfa | 2001 |
Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide.
Topics: Actuarial Analysis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide | 1991 |